

To: ellen.w.clayton@vanderbilt.edu <ellen.w.clayton@vanderbilt.edu>; jarnotb@api.org
<jarnotb@api.org>; benzene-erp@listserve.api.org <benzene-erp@listserve.api.org>; benzene-
srp@listserve.api.org <benzene-srp@listserve.api.org>
From: Jmricewas@aol.com <Jmricewas@aol.com>
Cc:
Bcc:
Received Date: 2004-08-27 15:49:00 GMT
Subject: Re: SRP & ERP.... Mid-year 2004 DP/ME Progress Report

Thanks, Ellen. I personally think the commercialization issue is most likely to arise from uses of the tissue bank after the Shanghai Health Study has formally concluded, so we need to give thought to how best to put appropriate notification and consent in place which will continue after funding stops.

Jerry

In a message dated 8/25/2004 10:26:55 AM Eastern Standard Time, ellen.w.clayton@vanderbilt.edu writes:

Subj: Re: SRP & ERP.... Mid-year 2004 DP/ME Progress Report
Date: 8/25/2004 10:26:55 AM Eastern Standard Time
From: ellen.w.clayton@vanderbilt.edu
To: jarnotb@api.org, benzene-erp@listserve.api.org, benzene-srp@listserve.api.org
File: PointsfortheShanghaistudy.doc (21504 bytes) DL Time (49333 bps): <1 minute
Sent from the Internet

Bruce and fellow panel members,

I am attaching a document that contains the bullet points I was asked for as well as residual concern about the commercialization issue. I am more than happy to get suggestions.

Ellen
